Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 22 peer-reviewed journal articles Updated
Infectious Disease · Human Immunodeficiency Virus Infection

Your Long-Term Health and Aging with HIV

At a Glance

With consistent HIV treatment, people with HIV can live long lives, but aging care should also address heart disease, kidney and bone health, weight changes, cholesterol, and cancer screening through coordinated HIV and primary care.

Thanks to modern Antiretroviral Therapy (ART), living a long, full life with HIV is the new standard [1]. However, as you age with the virus, your healthcare focus will shift from simply controlling the virus to managing your long-term “whole-body” health. This involves monitoring for comorbidities—other health conditions like heart disease or bone loss that can appear earlier or more frequently in people living with HIV [2].

The Role of Residual Immune Activation

Even when your viral load is “undetectable,” some residual immune activation can remain as a possible risk [3][4]. Over decades, this persistent, low-grade inflammation can contribute to an increased risk of cardiovascular disease, kidney issues, and certain cancers [5][6]. Inflammatory biomarkers are not routinely monitored to guide care; instead, the focus is on standard lifestyle interventions. Staying on your ART consistently is your first line of defense, as it keeps this inflammation as low as possible alongside quitting smoking and controlling blood pressure [7].

Metabolism and Weight Changes

Modern HIV medications are highly effective, but some have been linked to metabolic changes, specifically weight gain.

  • INSTIs and TAF: Research has found that Integrase Inhibitors (like dolutegravir or bictegravir) and the NRTI TAF (tenofovir alafenamide) are often associated with more weight gain than older drug classes [8][9].
  • Factors: This weight gain is most common in women, Black individuals, and those who started treatment with a very low CD4 count or a high viral load [10][9]. These are population-level associations, not inevitable drug effects; diet, aging, and other medicines contribute.
  • Management: If you experience significant weight gain, your doctor may review your diet and exercise or, in some cases, discuss modifying your medications [11]. Do not switch ART on your own [12].

Protecting Your Bones and Kidneys

Two versions of the drug tenofovir are commonly used today, and they affect your body differently over the long term.

Feature TDF (Tenofovir Disoproxil Fumarate) TAF (Tenofovir Alafenamide)
Kidney Health Higher risk of decline in kidney function and protein in the urine [13] Generally safer for the kidneys; lower risk of protein in the urine [14]
Bone Density Can lead to a greater decrease in bone mineral density [14] Consistently shows less impact on bone density than TDF [15]
Cholesterol Can have a slight cholesterol-lowering effect Can lead to higher levels of LDL (“bad”) cholesterol and triglycerides [10]

While TAF is generally more kidney- and bone-sparing, it is not suitable for every degree of renal impairment. TDF may be advantageous in some HBV or lipid contexts. Your doctor will weigh these tradeoffs [16][17].

Heart Health and Cancer Screening

Cardiovascular disease (CVD) is one of the most important long-term risks to manage, as it occurs about 1.5 to 2 times more often in people with HIV, which acts as a risk enhancer [18]. This risk is driven by a combination of inflammation and traditional factors like smoking, high blood pressure, and diabetes [5].

  • Heart Monitoring: Your care team should regularly check your blood pressure and lipids (cholesterol) and may use specialized “risk calculators” to decide if you need a statin [19][18].
  • Cancer Screening: While ART reduces the risk of many AIDS-related cancers, other types—such as lung, anal, and liver cancer—remain a concern as the HIV population ages [20][21]. Staying up to date with all age-appropriate screenings (like colonoscopies and mammograms) is essential. Screenings are individualized: your doctor will recommend HIV-specific cervical cancer screening, HPV vaccination, and individualize anal, liver, and lung screening based on your specific risks [22].

Managing HIV in the long term is a team effort. While your HIV specialist manages the virus, a primary care provider is equally vital to manage your heart, bones, and overall wellness [6][19].

Common questions in this guide

Can people with HIV live a long life as they get older?
Yes. Consistent antiretroviral therapy (ART) can help people with HIV live long, full lives. As you age, care also focuses on preventing and managing heart disease, kidney problems, bone loss, metabolic changes, and cancer.
Why is heart disease a concern for people aging with HIV?
HIV can raise the risk of heart disease even when treatment makes the viral load undetectable, partly because some low-level immune activation may persist. Smoking, high blood pressure, and diabetes can add to that risk. Regular blood pressure and cholesterol checks help your care team decide whether a statin or other prevention is appropriate.
Can HIV medications cause weight gain?
Some HIV regimens, especially those containing a class of medicines called integrase inhibitors or the drug tenofovir alafenamide (TAF), have been associated with weight gain. This effect is not inevitable, and diet, aging, and other medicines can also contribute. Tell your clinician about significant changes, and do not stop or switch ART without medical guidance.
How do TDF and TAF differ for kidney and bone health?
Tenofovir disoproxil fumarate (TDF) is more likely than TAF to reduce kidney function, cause protein in the urine, and lower bone mineral density. TAF generally has less impact on the kidneys and bones, but it may raise LDL cholesterol and triglycerides and is not appropriate for every level of kidney impairment. Your clinician should balance these tradeoffs with your other health needs.
What cancer screening is recommended when I have HIV?
People with HIV should keep up with age-appropriate screening, such as colon cancer screening and mammograms, while also following HIV-specific recommendations. Depending on your history and risks, your clinician may recommend cervical cancer screening, HPV vaccination, or individualized anal, liver, and lung cancer screening. The right schedule varies by person.
Why do I need a primary care doctor if I already see an HIV specialist?
An HIV specialist focuses on controlling the virus with ART, while a primary care clinician helps manage blood pressure, cholesterol, bone health, vaccinations, and age-appropriate screening. Working with both supports whole-body health as you age. They can coordinate decisions about medications and prevention.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Given that I'm aging with HIV, what is my current cardiovascular risk score (such as an ASCVD score), and should I consider starting a statin?
  2. 2.Does my current ART regimen contain TDF or TAF, and how are we balancing my kidney function, bone density, and lipid levels?
  3. 3.I’ve noticed some weight changes since starting my current medication; is this a known effect of my specific regimen, and should we consider any adjustments?
  4. 4.What specific cancer screenings, like cervical or anal screening, do I need beyond what is typically recommended for my age group?
  5. 5.Are my vaccinations, including HPV and pneumococcal vaccines, fully up to date?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (22)
  1. 1

    Comparison of Overall and Comorbidity-Free Life Expectancy Between Insured Adults With and Without HIV Infection, 2000-2016.

    Marcus JL, Leyden WA, Alexeeff SE, et al.

    JAMA network open 2020; (3(6)):e207954 doi:10.1001/jamanetworkopen.2020.7954.

    PMID: 32539152
  2. 2

    Geriatric Syndromes in Older HIV-Infected Adults.

    Greene M, Covinsky KE, Valcour V, et al.

    Journal of acquired immune deficiency syndromes (1999) 2015; (69(2)):161-7 doi:10.1097/QAI.0000000000000556.

    PMID: 26009828
  3. 3

    Suboptimal ART adherence, undetectable urine tenofovir, and higher C-reactive protein values.

    Ghanooni D, Heise MJ, Sassaman K, et al.

    AIDS (London, England) 2025; (39(13)):1975-1978 doi:10.1097/QAD.0000000000004288.

    PMID: 41000036
  4. 4

    Association of Prior SARS-CoV-2 Infection with Immune Activation in Virally Suppressed People Living with HIV.

    Suba MI, Rosca O, Hogea B, et al.

    Microorganisms 2026; (14(8)) doi:10.3390/microorganisms14081624.

    PMID: 42654971
  5. 5

    Managing HIV-associated inflammation and ageing in the era of modern ART.

    Bloch M, John M, Smith D, et al.

    HIV medicine 2020; (21 Suppl 3()):2-16 doi:10.1111/hiv.12952.

    PMID: 33022087
  6. 6

    Hypertension Is a Key Feature of the Metabolic Syndrome in Subjects Aging with HIV.

    Martin-Iguacel R, Negredo E, Peck R, Friis-Møller N

    Current hypertension reports 2016; (18(6)):46 doi:10.1007/s11906-016-0656-3.

    PMID: 27131801
  7. 7

    Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection.

    Sereti I, Krebs SJ, Phanuphak N, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (64(2)):124-131 doi:10.1093/cid/ciw683.

    PMID: 27737952
  8. 8

    Weight and Metabolic Outcomes in Naïve HIV Patients Treated with Integrase Inhibitor-Based Antiretroviral Therapy: A Systematic Review and Meta-Analysis.

    Valenzuela-Rodriguez G, Diaz-Arocutipa C, Collins JA, Hernandez AV

    Journal of clinical medicine 2023; (12(11)) doi:10.3390/jcm12113644.

    PMID: 37297839
  9. 9

    Weight Gain Following Initiation of Antiretroviral Therapy: Risk Factors in Randomized Comparative Clinical Trials.

    Sax PE, Erlandson KM, Lake JE, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2020; (71(6)):1379-1389 doi:10.1093/cid/ciz999.

    PMID: 31606734
  10. 10

    Risk of dyslipidaemia in people living with HIV who are taking tenofovir alafenamide: a systematic review and meta-analysis.

    Yoo JJ, Jung EA, Kim SG, et al.

    Journal of the International AIDS Society 2024; (27(9)):e26358 doi:10.1002/jia2.26358.

    PMID: 39301685
  11. 11

    A 48-Week, Randomized Controlled Trial of Doravirine for Individuals With HIV and Obesity on Integrase Inhibitors and Tenofovir Alafenamide: The Do IT Study (ACTG A5391).

    Koethe JR, Lake JE, Kantor A, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2026; (83(1)):e81-e89 doi:10.1093/cid/ciag196.

    PMID: 41847923
  12. 12

    Choosing between dual and three-drug antiretroviral therapy in aging and comorbid people with HIV: a narrative review.

    Cossu MV, Matone M, Iannone V, et al.

    Frontiers in reproductive health 2026; (8()):1805648 doi:10.3389/frph.2026.1805648.

    PMID: 42440622
  13. 13

    Evaluation of tenofovir alafenamide- versus tenofovir disoproxil fumarate-containing regimens on renal outcomes: systematic literature review and meta-analysis.

    Liang X, Park KY, Lee H, et al.

    BMC nephrology 2025; doi:10.1186/s12882-025-04628-9.

    PMID: 41272523
  14. 14

    Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials.

    Sax PE, Wohl D, Yin MT, et al.

    Lancet (London, England) 2015; (385(9987)):2606-15.

    PMID: 25890673
  15. 15

    Candidates for inclusion in a universal antiretroviral regimen: tenofovir alafenamide.

    Gotham D, Hill A, Pozniak AL

    Current opinion in HIV and AIDS 2017; (12(4)):324-333 doi:10.1097/COH.0000000000000379.

    PMID: 28403027
  16. 16

    Bone mineral density in virologically suppressed people aged 60 years or older with HIV-1 switching from a regimen containing tenofovir disoproxil fumarate to an elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide single-tablet regimen: a multicentre, open-label, phase 3b, randomised trial.

    Maggiolo F, Rizzardini G, Raffi F, et al.

    The lancet. HIV 2019; (6(10)):e655-e666 doi:10.1016/S2352-3018(19)30195-X.

    PMID: 31578954
  17. 17

    Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments.

    Achhra AC, Nugent M, Mocroft A, et al.

    Current HIV/AIDS reports 2016; (13(3)):149-57 doi:10.1007/s11904-016-0315-y.

    PMID: 27130284
  18. 18

    Risk of Cardiovascular Disease in an Aging HIV Population: Where Are We Now?

    Martin-Iguacel R, Llibre JM, Friis-Moller N

    Current HIV/AIDS reports 2015; (12(4)):375-87 doi:10.1007/s11904-015-0284-6.

    PMID: 26423407
  19. 19

    Cardiometabolic health in people with HIV: expert consensus review.

    Batterham RL, Bedimo RJ, Diaz RS, et al.

    The Journal of antimicrobial chemotherapy 2024; (79(6)):1218-1233 doi:10.1093/jac/dkae116.

    PMID: 38656584
  20. 20

    The interplay of comorbidity, disability, and physical activity among older adults living with HIV: insights from the CHANGE HIV study.

    Su TT, O'Brien KK, Zhabokritsky A, et al.

    BMC geriatrics 2026; (26(1)):159 doi:10.1186/s12877-025-06939-w.

    PMID: 41495670
  21. 21

    A Review of Chronic Comorbidities in Adults Living With HIV: State of the Science.

    Webel AR, Schexnayder J, Cioe PA, Zuñiga JA

    The Journal of the Association of Nurses in AIDS Care : JANAC 2021; (32(3)):322-346 doi:10.1097/JNC.0000000000000240.

    PMID: 33595986
  22. 22

    Frailty and Aging in HIV- Status Post 13 Years of National Awareness.

    Eke UA, Mohanty K, Gruber-Baldini AL, Ryan AS

    The Journal of frailty & aging 2023; (12(1)):49-58 doi:10.14283/jfa.2022.45.

    PMID: 36629084

This page is for informational purposes only and does not constitute medical advice about aging with HIV. Do not change ART or screening plans without discussing them with your HIV specialist and primary care provider.

Get notified when new evidence is published on HIV infectious disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.